PCI Pharma Boosts Services with Bedford Expansion
US-based PCI Pharma Services, a multinational CDMO, is spending $100 million to enhance its capacity and capabilities in aseptic liquid fill-finish and sterile lyophilization at its campus in Bedford, New Hampshire. The move follows the acquisition of Lyophilization Services of New England (LSNE) last December, which added the Bedford site to PCI’s network.
The investment includes the construction of a new multi-product facility, which will include an aseptic fill-finish line and twin lyophilizers with capacity to complete 400 vials per minute, helping accelerate speed to market. In addition, PCI will expand three other facilities at Bedford to add more aseptic fill-finish and lyophilization capabilities.
CEO Salim Haffar said the Bedford project is part of PCI’s broader strategy to provide integrated end-to-end drug development, manufacturing and packaging capabilities. “Our investment in these facilities will ensure that PCI continues to leverage new capabilities in complex formulations, aseptic fill-finish and lyophilization to meet the needs of our global clients, particularly as biologics continue their strong growth trajectory,” he said.
The company’s announcement is the latest in a series of worldwide expansions at sites that include Berlin, Germany; San Diego and Rockford, Illinois, USA; and Melbourne, Australia. PCI also announced last November that it was building a new Clinical Center of Excellence in Bridgewater, Massachusetts, which is due for completion this summer. It added that it will continue to further increase capacity and capabilities of other aseptic fill-finish facilities, including at Leon, Spain, and Madison, Wisconsin, USA.
Author: Elaine Burridge, Freelance Journalist
